However, early studies in the pre-PSA era often relied on acid phosphatase levels and patient symptoms as markers of response, as only 20% of patients with metastatic prostate cancer, have measurable soft tissue disease (Figg et al, 1996). This evidence concerns the gene KLK3 and metastatic prostate carcinoma.